RESUMO
Objective To assess the rate of metabolic syndrome among the patients of psoriasis
Methods It was a hospital based cross-sectional study. Fifty-eight patients, clinically and histopathologically diagnosed as psoriasis were selected by purposive sampling. Data including age, waist circumference and arterial blood pressure were recorded. Fasting blood glucose, triglyceride and HDL levels were measured. Metabolic syndrome was diagnosed by the presence of three or more of the five criteria of the modified version of National Cholesterol Education Programs Adult Panel III [ATPIII]
Results Out of 58 patients, 17 [29.3%] patients had metabolic syndrome. The prevalence of metabolic syndrome was higher in psoriatic patients in the 4th decade of life and predominant in male subjects. In psoriatic patients with metabolic syndrome, raised waist circumference >90 cm in men or >80 cm in women was found in 14 [82.3%], HDL cholesterol <40 mg/dl in 13 [76.5%], blood pressure >130/85 mm Hg in 16 [94.1%], and fasting blood sugar >5.6 mmol/L was noticed in 12 [70.6%] patients
Conclusion Metabolic syndrome was diagnosed in 29.3% of the psoriatic patients. Waist circumference, serum HDL cholesterol, blood pressure and fasting blood sugar were statistically significantly different [P<0.05] between patients with metabolic syndrome and without metabolic syndrome
RESUMO
Adverse drug reactions are common complications in drug therapy. About 3-8% of all hospital admissions are the results of adverse drug reactions, and these can cause significant disability to patients. To evaluate the clinical spectrum of all cutaneous adverse drug reactions and to establish the causal link between suspected drug and the reaction. This observational cross-sectional study was done among the patients having cutaneous drug eruptions. 50 consecutive patients were enrolled. Purposive sampling was done. In every patient a detailed history was taken. Examination was carried out to find out the type of cutaneous reactions. Data were collected in a predesigned structured questionnaire. Statistical analysis was done with the help of SPSS. Out of 50 respondents, 20% had a history of indigenous drug intake followed by 18% sulphonamides, 14% NSAIDs, 14% quinolones, 8% anticonvulsants, 8% cephalosporins, 6% penicillins, 4% antituberculous drugs, 4% metronidazole and 4% tetracyclines. 34% had maculopapular rash, 24% Stevens-Johnson syndrome, 12% exfoliative dermatitis, 10% urticaria, 8% fixed drug eruption, 8% erythema multiforme, 8% bullae, 6% vesicles, 2% lichenoid eruption and 2% scaly eruptions. Frequency distribution of the offending drugs and the adverse reactions revealed that cephradine was responsible for maculopapular rash, sulphonamides for Stevens-Johnson syndrome, indigenous medicines for exfoliative dermatitis, NSAIDs for urticaria and paracetamol for fixed drug eruption